Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis

Nefrologia

Volumn 33, Issue 1, 2013, Pages 77-84

  Piñera Haces, Celestino ^a   Izquierdo Ortiz, María J ^b   Francisco, Ángel L Martín de ^a   García Unzueta, M Teresa ^a   López Hoyos, Marcos ^a   Toyos, Carmen ^a   Allende, Natalia ^a   Quintela, Estrella ^a   Arias, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

25 hydroxyvitamin D; Bone mineral metabolism; Inflammation; Paricalcitol

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCIFEDIOL; DRUG DERIVATIVE; ERGOCALCIFEROL; PARICALCITOL; PHOSPHORUS; VITAMIN D;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCIFEDIOL; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; VITAMIN D;

EID: 84873718650     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Sep.11533     Document Type: Article

References (23)

1. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010;10:482-96.
2. Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, et al. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2011;15(2):161-8.
3. Levin A, Li YC. Vitamin D and analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005;68:1973-81.
4. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. VitaminD receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509-19.
5. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72(8):1004-13.
6. Gómez-Alonso C, Naves-Díaz ML, Fernández-Martín JL, Díaz-López JB, Fernández-Coto MT, Cannata-Andía JB. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl 2003;(85):S44-8.
7. Torregrosa JV, Bover J, Cannata J. Guías S.E.N. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-MM). Nefrologia 2011;31 Suppl 1:3-32.
8. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I, Galaktidou G. Paricalcitol reduces basal and lipopolysaccharideinduced (LPS) TNF-a and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol 2010;42:181-5.
9. Husain K, Suarez E, Isiadro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010;32:296-304.
10. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012;59(1):58-66.
11. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis. Nephrol Dial Transplant 2004;19:1154-60.
12. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52(2):249-55.
13. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-37.
14. Zittermann A, Gummert JF, Börgermann JB. Vitamin D deficiency and mortality. Curr Opin Clin Nutr Metab Care 2009;12(6):634-9.
15. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010;21(2):353-61.
16. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69(1):33-43.
17. Mehrotra R, Kermah D, Salusky IB, Wolg MS, Thadhani RI, Chiu YW, et al. Chronic kidney disease, hypovitaminosis D and mortality in the United States. Kidney Int 2009;76:977-83.
18. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:512-8.
19. Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010;121(1-2):193-8.
20. Addabbo F, Mallamaci F, Leonardis D, Tripepi R, Tripepi G, Goligorsky MS, et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007;22(12):3521-6.
21. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012;29(8):e142-50.
22. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
23. Haffner S, González C, Miettinen H, Kennedy E, Stern M. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996;10:1138-41.